Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disorders and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LPIN1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LPIN1 Recombinant Protein (Full-Length & Truncated) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for enzymatic and binding assays. |
View LPIN1 Products |
| Gene Delivery | LPIN1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to study lipid droplet formation and PAP enzyme activity. |
View LPIN1 Products |
| Benchmark Ab | Anti-LPIN1 Recombinant Antibody High-specificity positive control for Western Blot, IHC, and IP validation. |
View LPIN1 Products |
| Validator | LPIN1 siRNA Set For target knockdown verification in metabolic and tumor cell lines. |
View LPIN1 Products |
| Related Target A | LPIN2 Subfamily homolog. Crucial for selectivity profiling to prevent off-target inflammatory side effects. |
View LPIN2 Products |
| Related Target B | PPARGC1A (PGC-1α) Transcriptional coactivator partner. Essential for validating LPIN1's gene regulatory functions. |
View PPARGC1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily selectivity screening (LPIN1 vs LPIN2/3) | Highly purified human LPIN1, LPIN2, and LPIN3 ortholog proteins verified by mass spectrometry. |
| Dual-function profiling (Enzyme vs Coactivator) | Truncated constructs isolating the C-terminal PAP domain or N-terminal transcriptional domain. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and validated positive controls included. |
| False Positives | Validated siRNA transfection sets included for target-specific knockdown verification. |
Live LPIN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LPIN1 therapeutics is intensifying, with major players shifting focus from traditional metabolic pathways to oncology and inflammatory disease modulation. LPIN1 acts as a double-edged sword: its Mg2+-dependent phosphatidate phosphatase (PAP) activity controls diacylglycerol (DAG) synthesis, while its nuclear localization drives fatty acid oxidation via transcriptional coactivation. As first-generation small molecule inhibitors enter preclinical optimization, the next wave of R&D is targeting LPIN1-mediated lipogenesis in solid tumors and its gene-regulatory axis in rhabdomyolysis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Prostate Cancer, Triple-Negative Breast Cancer (TNBC) | Enzymatic Assay (Need high-purity, sequence-verified full-length LPIN1 protein) |
| Gene Therapy / mRNA | Orphan Drug Developers | LPIN1-Deficiency (Rhabdomyolysis) | Expression Validation (Need Lentivirus for stable cell line generation) |
| PROTACs / Degraders | Targeted Protein Degradation (TPD) Firms | Metabolic Syndrome, NASH | Binding & Degradation Profiling (Need pure LPIN1 for SPR/FP assays) |